Use of Anti – VEGF Therapy for ROP: When and How

Related

• 

  AMD Neovascular Expert Panel

  Robert L. Avery, MD

  Nizar S Abdelfattah, M.D.

  Nancy M. Holekamp, MD, FASRS

  Peter K. Kaiser, MD FASRS

  Pravin U. Dugel, MD

  Annual Meeting Talks

  2016

• 

  Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration

  David A. Eichenbaum, MD, FASRS

  Updates from the Field

  2018

• 

  Randomized Trial of PRP vs Intravitreal Ranibizumab Plus Deferred PRP for Proliferative Diabetic Retinopathy

  Andrew N. Antoszyk, MD FASRS

  Updates from the Field

  2016